Several studies have reported that celecoxib inhibits adhesion and invasion in gastric cancer, oral cancer, lung cancer, colon cancer and osteosarcoma cells through multiple cell signaling pathways such as NF-kB, MMP-2/9, E-cadherin, β-catenin and Akt/PKB [41–43]. This evidence concerns the gene NFKB1 and lip and oral cavity carcinoma.